<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868020</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0898</org_study_id>
    <secondary_id>NCI-2019-00597</secondary_id>
    <secondary_id>2018-0898</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03868020</nct_id>
  </id_info>
  <brief_title>Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease</brief_title>
  <official_title>Pilot Study of 18F Fluciclovine PET CT in Identification of the Primary in Patients With an Unknown Primary Head and Neck Squamous Cell Carcinoma Presenting With Metastatic Cervical Nodal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well fluciclovine F18 positron emission tomography
      (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell
      carcinoma in patients with cancer that has spread to the cervical lymph nodes. Fluciclovine
      F18 during a PET/CT scan may work better in helping doctors learn where the cancer started
      (called the site of origin) and directing treatment planning compared to standard
      fludeoxyglucose F-18 (FDG) PET-CT scans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate positive predictive value with a corresponding 95% confidence interval for
      fluciclovine F18 (18F fluciclovine) positron emission tomography computed tomography (PET CT)
      to detect a primary site of disease in patients presenting with cervical metastatic nodal
      disease but a head and neck primary site not apparent on CT of the neck with contrast
      (contrast enhanced-computed tomography, CE-CT).

      SECONDARY OBJECTIVES:

      I. To estimate positive predictive value with a corresponding 95% confidence interval for
      fludeoxyglucose F-18 (18F FDG) PET CT in the detection of a primary site of disease in
      patients presenting with cervical metastatic nodal disease but a head and neck primary site
      not apparent on CT of the neck with contrast.

      EXPLORATORY OBJECTIVES:

      I. To compare the lesion to background (L/B) ratios for nodal metastatic disease between 18F
      fluciclovine PET CT and 18F FDG PET CT.

      II. To estimate the sensitivity of 18F fluciclovine PET CT and 18F FDG PET CT to detect nodal
      disease.

      III. To evaluate for any trends in findings on 18F fluciclovine PET CT and human
      papillomavirus (HPV) status.

      OUTLINE:

      Patients receive fluciclovine F18 intravenously (IV) and undergo PET/CT scan over 20-30
      minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of the suspected lesions that are positive by the gold standard of pathology</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Positive predicative values will be estimated with a corresponding exact 95% confidence interval.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Lesion to background (L/B) ratios for nodal metastatic disease</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>L/B ratios for nodal metastatic disease will be compared between fluciclovine F18 (18F-flucivlovine) positron emission tomography computed tomography (PET CT) and fludeoxyglucose F-18 (18F FDG) PET CT. For lesions that are identified by both 18F FDG PET CT and 18F fluciclovine PET CT, paired t-tests will be used to compare the L/B ratios for primary sites. This analysis will be repeated for nodal metastatic disease sites that are identified by both methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sensitivity and specificity in detecting nodal disease</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>For nodes that are biopsied, pathology will serve as the gold standard, and the sensitivity and specificity will be estimated separately for 18F FDG PET CT and for 18F fluciclovine PET CT. For nodes that are not, 18F FDG PET CT will serve as the gold standard, and the sensitivity and specificity of 18F-flucivlovine PET CT will be estimated.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Metastatic Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Metastatic Squamous Cell Carcinoma in Cervical Lymph Node</condition>
  <arm_group>
    <arm_group_label>Diagnostic (fluciclovine F18 PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (fluciclovine F18 PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fluciclovine F18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (fluciclovine F18 PET/CT)</arm_group_label>
    <other_name>(18F)Fluciclovine</other_name>
    <other_name>(18F)GE-148</other_name>
    <other_name>18F-Fluciclovine</other_name>
    <other_name>[18F]FACBC</other_name>
    <other_name>Anti-(18f)FABC</other_name>
    <other_name>Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid</other_name>
    <other_name>Anti-[18F] FACBC</other_name>
    <other_name>Axumin</other_name>
    <other_name>Fluciclovine (18F)</other_name>
    <other_name>FLUCICLOVINE F-18</other_name>
    <other_name>GE-148 (18F)</other_name>
    <other_name>GE-148 F-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (fluciclovine F18 PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with biopsy proven metastatic cervical nodal squamous cell carcinoma

          -  CT of the neck with contrast that does not confidently identify a primary
             oropharyngeal site of disease

          -  Planned standard of care 18F-FDG PET CT examination

          -  Planned standard of care exam under anesthesia with oropharyngeal surgical biopsy

        Exclusion Criteria:

          -  Pregnant women

          -  Known allergy to FDG, fluciclovine, or iodine-based contrast agents

          -  Severe renal dysfunction (glomerular filtrate rate [within 30 days] less than 30)

          -  Inability to tolerate lying supine, relatively motionless for up to 1 hour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria K Gule-Monroe</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria K Gule-Monroe</last_name>
    <phone>281-546-7750</phone>
    <email>mgule@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria K. Gule-Monroe</last_name>
      <phone>281-546-7750</phone>
    </contact>
    <investigator>
      <last_name>Maria K. Gule-Monroe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

